SGS launches Germany’s first commercial cell sorting service

SWITZERLAND – SGS, a global leader in testing, inspection, and certification, has announced the launch of Germany’s first commercial cell sorting service for the biopharmaceutical industry.

This innovative service utilizes the advanced BD FACSAria™ Fusion system, enabling precise fluorescent-activated cell sorting (FACS) to support the development of advanced therapeutic medicinal products (ATMPs) and to drive advancements in cell and gene therapy.

Cell sorting technology, previously only available in academic settings, has now been brought to the commercial sector by SGS.

The BD FACSAria™ Fusion system allows for highly detailed cell characterization and sorting using both intra- and extra-cellular markers, which is crucial for the development of ATMPs.

By making this service commercially available, SGS enables biopharmaceutical companies to access cutting-edge solutions that are tailored to the specific needs of ATMP development.

The service offers not only validated biomarker panels in immunology and oncology but also enables the development of custom biomarkers and the isolation of rare cell populations.

This advanced system integrates seamlessly into laboratory workflows, boosting efficiency and flexibility during analysis.

Equipped with four lasers and 16 fluorescence detectors, the BD FACSAria™ Fusion system can measure thousands of cells and biomarkers simultaneously, including rare cell populations.

Its high-precision sorting capabilities can process up to 384 wells per plate, which is a significant advancement in cellular analysis.

Beyond just characterizing cells, the BD FACSAria™ Fusion system also facilitates the isolation, cultivation, and cryopreservation of rare cell populations, opening up new possibilities in research.

SGS conducts these operations in a biological safety level 2 (BSL-2) genetic engineering facility, which allows for the examination of genetically modified cells and expands the range of applications significantly.

This capability also makes it possible to identify potential toxic effects early and evaluate therapeutic success more effectively.

Understanding the importance of sample stability, SGS has set up a globally coordinated network of laboratories to reduce transfer times between sites.

This helps ensure that biopharmaceutical companies have timely access to reliable results.

Additionally, SGS’s service is enhanced by downstream applications, including immunological and molecular biological procedures.

Germany, as one of Europe’s largest markets for biopharmaceutical products, offers tremendous potential for growth, especially in cell and gene therapy.

 By integrating this advanced cell sorting service into its comprehensive biologics testing portfolio, SGS continues to support the development of innovative solutions in the biopharmaceutical sector.

This move highlights SGS’s commitment to accelerating patient therapies and ensuring the success of biotherapeutics that improve lives.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.

Newer Post

Thumbnail for SGS launches Germany’s first commercial cell sorting service

Investing in Innovation Africa (i3) to support African healthtech startups with US$1.6M investment

Older Post

Thumbnail for SGS launches Germany’s first commercial cell sorting service

US Emergency Waiver saves HIV treatment in Kenya after aid freeze

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.